The Solid Tumor Testing Market encompasses all the diagnostic products and technologies that are used for identifying, staging, and managing solid tumours in different organs such as the breast, lung, prostate, colon and more. Malignant neoplasms are also called solid tumors, which are unusual growths of tissues as unlike benign tumors they tend not to harbor cysts or liquid components. It can be either cystic (non malignant) or sclicular (malignant) and early diagnosis of the tumor is highly recommending for successful prognosis. The market includes diagnostic such facilities as NGS, IHC, PCR, and other molecular profiling that allows identifying specific features of tumoral tissues and contributing to creation of individual therapy regimens that improve patients’ quality of life.